Dear colleagues,
I would like to invite you to the lecture by Samantha Masineni called "CDK4/6 PROTACs: Advancing Targeted Protein Degradation for Pediatric Neuroblastoma". The lecture will be on Wednesday March 19, 2025 at 9AM in the room 1.09 at IMTM.
Abstract
Neuroblastoma, a highly aggressive pediatric cancer, often involves deregulation of the G1 checkpoint, with CDK4/6 overexpression and CDKN2A deletion driving uncontrolled proliferation. While CDK4/6 inhibitors have shown promise in adult cancers, their efficacy in neuroblastoma has been limited, leading only to growth inhibition without significant tumor regression.
To address this, we are developing CDK4/6-targeting PROTACs (Proteolysis-Targeting Chimeras), which selectively degrade these kinases via the ubiquitin-proteasome system. This approach aims to achieve sustained suppression of CDK4/6, improve tumor responses, and overcome the resistance seen with conventional inhibitors.